https://www.selleckchem.com/pr....oducts/pirtobrutinib
This study aimed to validate the residual tumor (R) descriptors proposed by the International Association for the Study of Lung Cancer (IASLC) for patients with pathologic N2 (pN2) NSCLC. We retrospectively reviewed the data of patients with pN2 NSCLC who underwent anatomical resection during the period 2004 to 2018. The R status classified using the Union for International Cancer Control (UICC) criteria was compared with that reassigned using the IASLC criteria. Survival analysis was performed using Cox proportional haza
Curtir
Comentario
Compartilhar
